Skip to main content
SpringerLink
Log in

Senescence Regulation by the p53 Protein Family

  • Protocol
  • First Online:
Cell Senescence

Part of the book series: Methods in Molecular Biology ((MIMB,volume 965))

Abstract

p53, a guardian of the genome, exerts its tumor suppression activity by regulating a large number of downstream targets involved in cell cycle arrest, DNA repair, apoptosis, and cellular senescence. Although p53-mediated apoptosis is able to kill cancer cells, a role for cellular senescence in p53-dependent tumor suppression is becoming clear. Mouse studies showed that activation of p53-induced premature senescence promotes tumor regression in vivo. However, p53-mediated cellular senescence also leads to aging-related phenotypes, such as tissue atrophy, stem cell depletion, and impaired wound healing. In addition, several p53 isoforms and two p53 homologs, p63 and p73, have been shown to play a role in cellular senescence and/or aging. Importantly, p53, p63, and p73 are necessary for the maintenance of adult stem cells. Therefore, understanding the dual role the p53 protein family in cancer and aging is critical to solve cancer and longevity in the future. In this chapter, we provide an overview on how p53, p63, p73, and their isoforms regulate cellular senescence and aging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 76:2420–2424

    Article  PubMed  CAS  Google Scholar 

  2. Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261–263

    Article  PubMed  CAS  Google Scholar 

  3. Linzer DI, Levine AJ (1979) Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52

    Article  PubMed  CAS  Google Scholar 

  4. Melero JA, Stitt DT, Mangel WF, Carroll RB (1979) Identification of new polypeptide species (48–55 K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology 93:466–480

    Article  PubMed  CAS  Google Scholar 

  5. Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1:a001883

    Article  PubMed  CAS  Google Scholar 

  6. Beckerman R, Prives C (2010) Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2:a000935

    Article  PubMed  Google Scholar 

  7. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629

    Article  PubMed  CAS  Google Scholar 

  8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221

    Article  PubMed  CAS  Google Scholar 

  9. Donehower LA (2009) Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol 1:a001081

    Article  PubMed  CAS  Google Scholar 

  10. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348:747–749

    Article  PubMed  CAS  Google Scholar 

  11. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238

    Article  PubMed  CAS  Google Scholar 

  12. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660

    Article  PubMed  CAS  Google Scholar 

  13. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665

    Article  PubMed  CAS  Google Scholar 

  14. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725–730

    Article  PubMed  CAS  Google Scholar 

  15. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585–621

    Article  PubMed  CAS  Google Scholar 

  16. Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37:614–636

    Article  PubMed  CAS  Google Scholar 

  17. Matsumura T, Zerrudo Z, Hayflick L (1979) Senescent human diploid cells in culture: survival, DNA synthesis and morphology. J Gerontol 34:328–334

    Article  PubMed  CAS  Google Scholar 

  18. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367

    Article  PubMed  CAS  Google Scholar 

  19. d’Adda di Fagagna F, Teo SH, Jackson SP (2004) Functional links between telomeres and proteins of the DNA-damage response. Genes Dev 18:1781–1799

    Article  PubMed  Google Scholar 

  20. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352

    Article  PubMed  CAS  Google Scholar 

  21. Hayflick L (2000) The illusion of cell immortality. Br J Cancer 83:841–846

    Article  PubMed  CAS  Google Scholar 

  22. Dimri GP (2005) What has senescence got to do with cancer? Cancer Cell 7:505–512

    Article  PubMed  CAS  Google Scholar 

  23. Artandi SE, Attardi LD (2005) Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 331:881–890

    Article  PubMed  CAS  Google Scholar 

  24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593–602

    Article  PubMed  CAS  Google Scholar 

  25. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59:3761–3767

    PubMed  CAS  Google Scholar 

  26. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62:1876–1883

    Google Scholar 

  27. Ben-Porath I, Weinberg RA (2005) The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 37:961–976

    Article  PubMed  CAS  Google Scholar 

  28. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, Kato Y, Honma K (2002) Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 419:841–844

    Article  PubMed  CAS  Google Scholar 

  29. Harms KL, Chen X (2006) The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 13(6):890–897

    Article  PubMed  CAS  Google Scholar 

  30. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1:45–49

    Article  PubMed  CAS  Google Scholar 

  31. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461–468

    PubMed  CAS  Google Scholar 

  32. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299

    Article  PubMed  CAS  Google Scholar 

  33. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25–27

    Article  PubMed  CAS  Google Scholar 

  34. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303

    Article  PubMed  CAS  Google Scholar 

  35. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13:941–950

    Article  PubMed  CAS  Google Scholar 

  36. Olsson A, Manzl C, Strasser A, Villunger A (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14:1561–1575

    Article  PubMed  CAS  Google Scholar 

  37. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923

    Article  PubMed  CAS  Google Scholar 

  38. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D (1999) Rapid ATM-dependent phosphorylation of MDM2 ­precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A 96:14973–14977

    Article  PubMed  CAS  Google Scholar 

  39. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E, Oren M (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15:1067–1077

    Article  PubMed  CAS  Google Scholar 

  40. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275–283

    Article  PubMed  CAS  Google Scholar 

  41. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074–1080

    Article  PubMed  CAS  Google Scholar 

  42. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606

    Article  PubMed  CAS  Google Scholar 

  43. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377–381

    Article  PubMed  CAS  Google Scholar 

  44. Dai C, Gu W (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16:528–536

    Article  PubMed  CAS  Google Scholar 

  45. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML (2006) Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173:533–544

    Article  PubMed  CAS  Google Scholar 

  46. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24:841–851

    Article  PubMed  CAS  Google Scholar 

  47. Tang Y, Luo J, Zhang W, Gu W (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24:827–839

    Article  PubMed  CAS  Google Scholar 

  48. Charvet C, Wissler M, Brauns-Schubert P, Wang SJ, Tang Y, Sigloch FC, Mellert H, Brandenburg M, Lindner SE, Breit B, Green DR, McMahon SB, Borner C, Gu W, Maurer U (2011) Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol Cell 42:584–596

    Article  PubMed  CAS  Google Scholar 

  49. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612–626

    Article  PubMed  CAS  Google Scholar 

  50. Mazan-Mamczarz K, Galban S, Lopez de Silanes I, Martindale JL, Atasoy U, Keene JD, Gorospe M (2003) RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100:8354–8359

    Article  PubMed  CAS  Google Scholar 

  51. Takagi M, Absalon MJ, McLure KG, Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123:49–63

    Article  PubMed  CAS  Google Scholar 

  52. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M (2008) Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell 32:180–189

    Article  PubMed  CAS  Google Scholar 

  53. Zhang J, Cho SJ, Shu L, Yan W, Guerrero T, Kent M, Skorupski K, Chen H, Chen X (2011) Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev 25:1528–1543

    Article  PubMed  CAS  Google Scholar 

  54. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B (2009) MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23:862–876

    Article  PubMed  CAS  Google Scholar 

  55. Zhang Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, Ramratnam B (2009) MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 583:3725–3730

    Article  PubMed  CAS  Google Scholar 

  56. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z (2010) Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 38:689–699

    Article  PubMed  CAS  Google Scholar 

  57. Karlseder J, Smogorzewska A, de Lange T (2002) Senescence induced by altered telomere state, not telomere loss. Science 295:2446–2449

    Article  PubMed  CAS  Google Scholar 

  58. von Zglinicki T, Saretzki G, Ladhoff J, d’Adda di Fagagna F, Jackson SP (2005) Human cell senescence as a DNA damage response. Mech Ageing Dev 126:111–117

    Article  CAS  Google Scholar 

  59. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460

    Article  PubMed  CAS  Google Scholar 

  60. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426:194–198

    Article  PubMed  CAS  Google Scholar 

  61. Takai H, Smogorzewska A, de Lange T (2003) DNA damage foci at dysfunctional telomeres. Curr Biol 13:1549–1556

    Article  PubMed  CAS  Google Scholar 

  62. Pandita TK (2002) ATM function and telomere stability. Oncogene 21:611–618

    Article  PubMed  CAS  Google Scholar 

  63. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14:501–513

    Article  PubMed  CAS  Google Scholar 

  64. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527–538

    Article  PubMed  CAS  Google Scholar 

  65. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406:641–645

    Article  PubMed  CAS  Google Scholar 

  66. Kemp CJ, Donehower LA, Bradley A, Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813–822

    Article  PubMed  CAS  Google Scholar 

  67. McDuff FK, Turner SD (2011) Jailbreak: oncogene-induced senescence and its evasion. Cell Signal 23:6–13

    Article  PubMed  CAS  Google Scholar 

  68. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24:2463–2479

    Article  PubMed  CAS  Google Scholar 

  69. Qian Y, Chen X (2010) Tumor suppression by p53: making cells senescent. Histol Histopathol 25:515–526

    PubMed  CAS  Google Scholar 

  70. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12:3008–3019

    Article  PubMed  CAS  Google Scholar 

  71. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67:2098–2106

    Article  PubMed  CAS  Google Scholar 

  72. Land H, Parada LF, Weinberg RA (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596–602

    Article  PubMed  CAS  Google Scholar 

  73. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR 3rd, Wright PE, Han J (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 128:295–308

    Article  PubMed  CAS  Google Scholar 

  74. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, Sun P (2002) Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22:3389–3403

    Article  PubMed  CAS  Google Scholar 

  75. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K (2005) Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 25:220–232

    Article  PubMed  CAS  Google Scholar 

  76. Palmero I, Pantoja C, Serrano M (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395:125–126

    Article  PubMed  CAS  Google Scholar 

  77. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395:124–125

    Article  PubMed  CAS  Google Scholar 

  78. Inoue K, Roussel MF, Sherr CJ (1999) Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A 96:3993–3998

    Article  PubMed  CAS  Google Scholar 

  79. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440

    Article  PubMed  CAS  Google Scholar 

  80. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000

    Article  PubMed  CAS  Google Scholar 

  81. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723

    Article  PubMed  CAS  Google Scholar 

  82. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22–27

    Article  PubMed  CAS  Google Scholar 

  83. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734

    Article  PubMed  CAS  Google Scholar 

  84. Tao W, Levine AJ (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 96:6937–6941

    Article  PubMed  CAS  Google Scholar 

  85. Wei W, Hemmer RM, Sedivy JM (2001) Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol 21:6748–6757

    Article  PubMed  CAS  Google Scholar 

  86. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633–637

    Article  PubMed  CAS  Google Scholar 

  87. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d’Adda di Fagagna F (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444:638–642

    Article  PubMed  CAS  Google Scholar 

  88. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352–1355

    Article  PubMed  CAS  Google Scholar 

  89. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G (2007) The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21:43–48

    Article  PubMed  CAS  Google Scholar 

  90. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649–1652

    Article  PubMed  CAS  Google Scholar 

  91. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274:7936–7940

    Article  PubMed  CAS  Google Scholar 

  92. Lloyd AC (2002) Limits to lifespan. Nat Cell Biol 4:E25–E27

    Article  PubMed  CAS  Google Scholar 

  93. Wynford-Thomas D (1999) Cellular senescence and cancer. J Pathol 187:100–111

    Article  PubMed  CAS  Google Scholar 

  94. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307–315

    Article  PubMed  CAS  Google Scholar 

  95. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M (2005) Tumour biology: senescence in premalignant tumours. Nature 436:642

    Article  PubMed  CAS  Google Scholar 

  96. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127:1323–1334

    Article  PubMed  CAS  Google Scholar 

  97. Wang Y, Blandino G, Oren M, Givol D (1998) Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 17:1923–1930

    Article  PubMed  CAS  Google Scholar 

  98. Sugrue MM, Shin DY, Lee SW, Aaronson SA (1997) Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci U S A 94:9648–9653

    Article  PubMed  CAS  Google Scholar 

  99. Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102:1536–1546

    Article  PubMed  CAS  Google Scholar 

  100. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB (1999) Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18:4808–4818

    Article  PubMed  CAS  Google Scholar 

  101. Qian Y, Zhang J, Yan B, Chen X (2008) DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 283:2896–2905

    Article  PubMed  CAS  Google Scholar 

  102. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA (1999) p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18:2789–2797

    Article  PubMed  CAS  Google Scholar 

  103. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES (2006) Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5:187–195

    Article  PubMed  CAS  Google Scholar 

  104. Kurz DJ, Decary S, Hong Y, Erusalimsky JD (2000) Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113(Pt 20):3613–3622

    PubMed  CAS  Google Scholar 

  105. Le Gall JY, Khoi TD, Glaise D, Le treut A, Brissot P, Guillouzo A (1979) Lysosomal enzyme activities during ageing of adult human liver cell lines. Mech Ageing Dev 11:287–293

    Article  PubMed  CAS  Google Scholar 

  106. Untergasser G, Gander R, Rumpold H, Heinrich E, Plas E, Berger P (2003) TGF-beta cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Exp Gerontol 38:1179–1188

    Article  PubMed  CAS  Google Scholar 

  107. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703–716

    Article  PubMed  CAS  Google Scholar 

  108. Zhang R, Chen W, Adams PD (2007) Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 27:2343–2358

    Article  PubMed  CAS  Google Scholar 

  109. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S (2006) Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 26:4161–4171

    Article  PubMed  CAS  Google Scholar 

  110. Lawless C, Wang C, Jurk D, Merz A, Zglinicki T, Passos JF (2010) Quantitative assessment of markers for cell senescence. Exp Gerontol 45:772–778

    Article  PubMed  CAS  Google Scholar 

  111. Chan HM, Narita M, Lowe SW, Livingston DM (2005) The p400 E1A-associated protein is a novel component of the p53  –  >  p21 senescence pathway. Genes Dev 19:196–201

    Article  PubMed  CAS  Google Scholar 

  112. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, Lowe SW (2004) PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13:523–535

    Article  PubMed  Google Scholar 

  113. Kunz C, Pebler S, Otte J, von der Ahe D (1995) Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 23:3710–3717

    Article  PubMed  CAS  Google Scholar 

  114. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90–98

    Article  PubMed  CAS  Google Scholar 

  115. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207–210

    Article  PubMed  CAS  Google Scholar 

  116. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015–2027

    PubMed  CAS  Google Scholar 

  117. Mu XC, Higgins PJ (1995) Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts. J Cell Physiol 165:647–657

    Article  PubMed  CAS  Google Scholar 

  118. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825

    Article  PubMed  CAS  Google Scholar 

  119. Afshari CA, Nichols MA, Xiong Y, Mudryj M (1996) A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth Differ 7:979–988

    PubMed  CAS  Google Scholar 

  120. Li R, Waga S, Hannon GJ, Beach D, Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534–537

    Article  PubMed  CAS  Google Scholar 

  121. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578

    Article  PubMed  CAS  Google Scholar 

  122. Vernier M, Bourdeau V, Gaumont-Leclerc MF, Moiseeva O, Begin V, Saad F, Mes-Masson AM, Ferbeyre G (2011) Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 25:41–50

    Article  PubMed  CAS  Google Scholar 

  123. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A (2002) Deconstructing PML-induced premature senescence. EMBO J 21:3358–3369

    Article  PubMed  CAS  Google Scholar 

  124. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6:665–672

    Article  PubMed  CAS  Google Scholar 

  125. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y (2003) The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278:33134–33141

    Article  PubMed  CAS  Google Scholar 

  126. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21:2383–2396

    Article  PubMed  CAS  Google Scholar 

  127. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25–40

    Article  PubMed  CAS  Google Scholar 

  128. Qian Y, Chen X (2008) ID1, inhibitor of differentiation/DNA binding, is an effector of the p53-dependent DNA damage response pathway. J Biol Chem 283:22410–22416

    Article  PubMed  CAS  Google Scholar 

  129. Hara E, Yamaguchi T, Nojima H, Ide T, Campisi J, Okayama H, Oda K (1994) Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J Biol Chem 269:2139–2145

    PubMed  CAS  Google Scholar 

  130. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ (2010) YPEL3, a p53-regulated gene that induces cellular senescence. Cancer Res 70:3566–3575

    Article  PubMed  CAS  Google Scholar 

  131. Wheaton K, Muir J, Ma W, Benchimol S (2010) BTG2 antagonizes Pin1 in response to mitogens and telomere disruption during replicative senescence. Aging Cell 9:747–760

    Article  PubMed  CAS  Google Scholar 

  132. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ (2007) A microRNA component of the p53 tumour suppressor network. Nature 447:1130–1134

    Article  PubMed  CAS  Google Scholar 

  133. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104:15472–15477

    Article  PubMed  CAS  Google Scholar 

  134. Kapic A, Helmbold H, Reimer R, Klotzsche O, Deppert W, Bohn W (2006) Cooperation between p53 and p130(Rb2) in induction of cellular senescence. Cell Death Differ 13:324–334

    Article  PubMed  CAS  Google Scholar 

  135. Jackson JG, Pereira-Smith OM (2006) Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 26:2501–2510

    Article  PubMed  CAS  Google Scholar 

  136. Helmbold H, Komm N, Deppert W, Bohn W (2009) Rb2/p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence. Oncogene 28:3456–3467

    Article  PubMed  CAS  Google Scholar 

  137. Khoury MP, Bourdon JC (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2:a000927

    Article  PubMed  CAS  Google Scholar 

  138. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122–2137

    Article  PubMed  CAS  Google Scholar 

  139. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, Oren M, Hainaut P (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722–6728

    Article  PubMed  CAS  Google Scholar 

  140. Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24:7987–7997

    Article  PubMed  CAS  Google Scholar 

  141. Yin Y, Stephen CW, Luciani MG, Fahraeus R (2002) p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4:462–467

    Article  PubMed  CAS  Google Scholar 

  142. Rovinski B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S (1987) Deletion of 5′-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol Cell Biol 7:847–853

    PubMed  CAS  Google Scholar 

  143. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T (1996) The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813–818

    PubMed  CAS  Google Scholar 

  144. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon JC, Lane DP, Harris CC (2009) p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11:1135–1142

    Article  PubMed  CAS  Google Scholar 

  145. Graupner V, Schulze-Osthoff K, Essmann F, Janicke RU (2009) Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 8:1238–1248

    Article  PubMed  CAS  Google Scholar 

  146. Olivares-Illana V, Fahraeus R (2010) p53 isoforms gain functions. Oncogene 29:5113–5119

    Article  PubMed  CAS  Google Scholar 

  147. Kirkwood TB, Austad SN (2000) Why do we age? Nature 408:233–238

    Article  PubMed  CAS  Google Scholar 

  148. Sharpless NE, DePinho RA (2007) How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 8:703–713

    Article  PubMed  CAS  Google Scholar 

  149. Sharpless NE, DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J Clin Invest 113:160–168

    PubMed  CAS  Google Scholar 

  150. Kim WY, Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127:265–275

    Article  PubMed  CAS  Google Scholar 

  151. Papazoglu C, Mills AA (2007) p53: at the crossroad between cancer and ageing. J Pathol 211:124–133

    Article  PubMed  CAS  Google Scholar 

  152. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley A, Donehower LA (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415:45–53

    Article  PubMed  CAS  Google Scholar 

  153. Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA (2007) Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev 128:717–730

    Article  PubMed  CAS  Google Scholar 

  154. Gentry A, Venkatachalam S (2005) Complicating the role of p53 in aging. Aging Cell 4:157–160

    Article  PubMed  CAS  Google Scholar 

  155. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306–319

    Article  PubMed  CAS  Google Scholar 

  156. Tatar M, Bartke A, Antebi A (2003) The endocrine regulation of aging by insulin-like signals. Science 299:1346–1351

    Article  PubMed  CAS  Google Scholar 

  157. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M (2005) Suppression of aging in mice by the hormone Klotho. Science 309:1829–1833

    Article  PubMed  CAS  Google Scholar 

  158. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982–3991

    PubMed  CAS  Google Scholar 

  159. Lim DS, Vogel H, Willerford DM, Sands AT, Platt KA, Hasty P (2000) Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol Cell Biol 20:3772–3780

    Article  PubMed  CAS  Google Scholar 

  160. Cao L, Li W, Kim S, Brodie SG, Deng CX (2003) Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev 17:201–213

    Article  PubMed  CAS  Google Scholar 

  161. Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR, Sanchez LM, Zhou Z, Rodriguez FJ, Stewart CL, Vega JA, Tryggvason K, Freije JM, Lopez-Otin C (2005) Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 437:564–568

    Article  PubMed  CAS  Google Scholar 

  162. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG (1999) The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402:309–313

    Article  PubMed  CAS  Google Scholar 

  163. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, Serrano M (2002) “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21:6225–6235

    Article  PubMed  CAS  Google Scholar 

  164. Matheu A, Pantoja C, Efeyan A, Criado LM, Martin-Caballero J, Flores JM, Klatt P, Serrano M (2004) Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev 18:2736–2746

    Article  PubMed  CAS  Google Scholar 

  165. Mendrysa SM, O’Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20:16–21

    Article  PubMed  CAS  Google Scholar 

  166. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Vina J, Blasco MA, Serrano M (2007) Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448:375–379

    Article  PubMed  CAS  Google Scholar 

  167. Feng Z, Lin M, Wu R (2011) The regulation of aging and longevity: a new and complex role of p53. Genes Cancer 2:443–452

    Article  PubMed  CAS  Google Scholar 

  168. Feng Z, Levine AJ (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20:427–434

    Article  PubMed  CAS  Google Scholar 

  169. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2:344–352

    CAS  Google Scholar 

  170. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853–2868

    Article  PubMed  CAS  Google Scholar 

  171. de Keizer PL, Laberge RM, Campisi J (2010) p53: pro-aging or pro-longevity? Aging (Albany NY) 2:377–379

    Google Scholar 

  172. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819

    Article  PubMed  CAS  Google Scholar 

  173. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305–316

    Article  PubMed  CAS  Google Scholar 

  174. Harms K, Nozell S, Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61:822–842

    Article  PubMed  CAS  Google Scholar 

  175. Moll UM, Slade N (2004) p63 and p73: roles in development and tumor formation. Mol Cancer Res 2:371–386

    PubMed  CAS  Google Scholar 

  176. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, D’Erchia AM (2009) Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res 37:6092–6104

    Article  PubMed  CAS  Google Scholar 

  177. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 188:1763–1768

    Article  PubMed  Google Scholar 

  178. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A, Levrero M, Knight RA (1999) Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ 6:389–390

    Article  PubMed  CAS  Google Scholar 

  179. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S (2002) Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 62:636–641

    PubMed  CAS  Google Scholar 

  180. Scaruffi P, Casciano I, Masiero L, Basso G, Romani M, Tonini GP (2000) Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL differentiation. Leukemia 14:518–519

    Article  PubMed  CAS  Google Scholar 

  181. Stiewe T, Theseling CC, Putzer BM (2002) Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277:14177–14185

    Article  PubMed  CAS  Google Scholar 

  182. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708–713

    Article  PubMed  CAS  Google Scholar 

  183. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714–718

    Article  PubMed  CAS  Google Scholar 

  184. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103

    Article  PubMed  CAS  Google Scholar 

  185. Zhu J, Jiang J, Zhou W, Chen X (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58:5061–5065

    PubMed  CAS  Google Scholar 

  186. Dohn M, Zhang S, Chen X (2001) p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20:3193–3205

    Article  PubMed  CAS  Google Scholar 

  187. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, Melino G, Aberdam D (2011) DeltaNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 18:887–896

    Article  PubMed  CAS  Google Scholar 

  188. Medawar A, Virolle T, Rostagno P, de la Forest-Divonne S, Gambaro K, Rouleau M, Aberdam D (2008) DeltaNp63 is essential for epidermal commitment of embryonic stem cells. PLoS One 3:e3441

    Article  PubMed  CAS  Google Scholar 

  189. Lee H, Kimelman D (2002) A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2:607–616

    Article  PubMed  CAS  Google Scholar 

  190. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18:126–131

    Article  PubMed  CAS  Google Scholar 

  191. Su X, Paris M, Gi YJ, Tsai KY, Cho MS, Lin YL, Biernaskie JA, Sinha S, Prives C, Pevny LH, Miller FD, Flores ER (2009) TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 5:64–75

    Article  PubMed  CAS  Google Scholar 

  192. Koster MI, Marinari B, Payne AS, Kantaputra PN, Costanzo A, Roop DR (2009) DeltaNp63 knockdown mice: a mouse model for AEC syndrome. Am J Med Genet A 149A:1942–1947

    Article  PubMed  CAS  Google Scholar 

  193. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I, Flores ER (2010) TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467:986–990

    Article  PubMed  CAS  Google Scholar 

  194. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363–373

    Article  PubMed  CAS  Google Scholar 

  195. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 19:1986–1999

    Article  PubMed  CAS  Google Scholar 

  196. Holder-Espinasse M, Martin-Coignard D, Escande F, Manouvrier-Hanu S (2007) A new mutation in TP63 is associated with age-related pathology. Eur J Hum Genet 15:1115–1120

    Article  PubMed  CAS  Google Scholar 

  197. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Michurina TV, Enikolopov G, Muthuswamy SK, Mills AA (2011) DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 8:164–176

    Article  PubMed  CAS  Google Scholar 

  198. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11:1451–1457

    Article  PubMed  CAS  Google Scholar 

  199. Keyes WM, Mills AA (2006) p63: a new link between senescence and aging. Cell Cycle 5:260–265

    Article  PubMed  CAS  Google Scholar 

  200. Nahor I, Abramovitch S, Engeland K, Werner H (2005) The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res 15:388–396

    Article  PubMed  CAS  Google Scholar 

  201. Stiewe T, Putzer BM (2000) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26:464–469

    Article  PubMed  CAS  Google Scholar 

  202. Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389:191–194

    Article  PubMed  CAS  Google Scholar 

  203. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407:645–648

    Article  PubMed  CAS  Google Scholar 

  204. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF (2000) A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407:642–645

    Article  PubMed  CAS  Google Scholar 

  205. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr (2003) Chemosensitivity linked to p73 function. Cancer Cell 3:403–410

    Article  PubMed  CAS  Google Scholar 

  206. Zhu J, Nozell S, Wang J, Jiang J, Zhou W, Chen X (2001) p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 20:4050–4057

    Article  PubMed  CAS  Google Scholar 

  207. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806–809

    Article  PubMed  CAS  Google Scholar 

  208. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, Mak TW (2008) TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677–2691

    Article  PubMed  CAS  Google Scholar 

  209. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD, Mak TW (2010) Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 24:549–560

    Article  PubMed  CAS  Google Scholar 

  210. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD (2000) An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304–306

    Article  PubMed  CAS  Google Scholar 

  211. Pozniak CD, Barnabe-Heider F, Rymar VV, Lee AF, Sadikot AF, Miller FD (2002) p73 is required for survival and maintenance of CNS neurons. J Neurosci 22:9800–9809

    PubMed  CAS  Google Scholar 

  212. Tissir F, Ravni A, Achouri Y, Riethmacher D, Meyer G, Goffinet AM (2009) DeltaNp73 regulates neuronal survival in vivo. Proc Natl Acad Sci U S A 106:16871–16876

    Article  PubMed  CAS  Google Scholar 

  213. Fujitani M, Cancino GI, Dugani CB, Weaver IC, Gauthier-Fisher A, Paquin A, Mak TW, Wojtowicz MJ, Miller FD, Kaplan DR (2010) TAp73 acts via the bHLH Hey2 to promote long-term maintenance of neural precursors. Curr Biol 20:2058–2065

    Article  PubMed  CAS  Google Scholar 

  214. Wetzel MK, Naska S, Laliberte CL, Rymar VV, Fujitani M, Biernaskie JA, Cole CJ, Lerch JP, Spring S, Wang SH, Frankland PW, Henkelman RM, Josselyn SA, Sadikot AF, Miller FD, Kaplan DR (2008) p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer’s disease. Neuron 59:708–721

    Article  PubMed  CAS  Google Scholar 

  215. Werner H, Karnieli E, Rauscher FJ, LeRoith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 93:8318–8323

    Article  PubMed  CAS  Google Scholar 

  216. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67:3043–3053

    Article  PubMed  CAS  Google Scholar 

  217. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G, and Mak TW (2012) TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 26:2009–2014

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comparative Oncology Laboratory, University of California, Davis, CA, USA

    Yingjuan Qian & Xinbin Chen

Authors
  1. Yingjuan Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinbin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinbin Chen .

Editor information

Editors and Affiliations

  1. Institut Gustave Roussy, Pavillon de Recherche 1, INSERM U848, rue C. Desmoulins 39, Villejuif, 94085, France

    Lorenzo Galluzzi

  2. Institut Gustave Roussy, Pavillon de Recherche 1, INSERM U848, rue C. Desmoulins 39, Villejuif CEDEX, 94085, France

    Ilio Vitale

  3. Institut Gustave Roussy, Pavillon de Recherche 1, INSERM U848, rue C. Desmoulins 39, Villejuif CEDEX, 94085, France

    Oliver Kepp

  4. Institut Gustave Roussy (IGR), Pavillon de Recherche 1, INSERM, U848, rue Camille-Desmoulins 39, Villejuif, 94805, France

    Guido Kroemer

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Busincess Media, LLC

About this protocol

Cite this protocol

Qian, Y., Chen, X. (2013). Senescence Regulation by the p53 Protein Family. In: Galluzzi, L., Vitale, I., Kepp, O., Kroemer, G. (eds) Cell Senescence. Methods in Molecular Biology, vol 965. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-239-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-239-1_3

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-238-4

  • Online ISBN: 978-1-62703-239-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation